Live Breaking News & Updates on Clinical hold letter
Stay updated with breaking news from Clinical hold letter. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Acurx Pharmaceuticals Inc. continues to post positive data for its lead candidate ibezapolstat but that didn’t stop the stock from tumbling. The antibiotic outperformed vancomycin in a phase IIb study treating Clostridioides difficile infection (CDI). Vancomycin is a standard of care in the indication. Ibezapolstat eradicated fecal CDI at day 3 in 15 of 16 patients compared to vancomycin, which eradicated fecal CDI in 10 of 14 patients.
Allakos Inc. terminated all development of its lead drug, anti-Siglec-8 antibody lirentelimab (AK-002), and is cutting its workforce in half, following phase II failures for atopic dermatitis and chronic spontaneous urticaria. The San Carlos, Calif.-based company will now focus on phase I trials for anti-Siglec-6 antibody AK-006 as part of a restructuring that stretches the runway into mid-2026. Shares (NASDAQ:ALLK) sank by 60.2%, down $1.80, to close at $1.19 on Jan. 16.
>> most participants taken >> most participants taken before guard also haou. less muscle weakness, and you have been off guard treatment scheduleed is designed just for you in a clinical. y of i the most common side effects included and respiratory tract infectionsnf and headache. this guard may increase the risk of infection. the risk of infection. tell your doctor ailabl if you haveon. a history of infections or symptoms of an infection, this guard can cause allergic reactions available as guard for i.v infusion and also as vive guard. >> hi true low for subcutaneous >> hi true low for subcutaneous injection additionalal effects for vive guard are true though they include injection site reactions to talk to your neurologist about vive guard. >> why you shouldn't do that and what and you that i mean connecting to skilled professionals to get all your home projects done well so you can focus on the important stuff. i mean see millions of ratings and reviews so you can feel comfort in it means comparing quotes or booking at an upfront price so you can choose the best price for you because we want everyone to get
Pharmaceutical delivery system developer N4 Pharma reported significant progress in its research efforts to enhance viral vector performance using Nuvec on Monday.
Clinical-stage biotechnology company Destiny Pharma said in a year-end update on Thursday that its primary focus remained on realising the full potential of its XF-73 Nasal asset.
By Kelvin McDonald of Whakaata Maori How many whānau can say they have walked the length of Aotearoa at least once in their lifetime, let alone four times?...
A Christchurch -based medicinal marijuana company is leading New Zealand’s first clinical trial testing medicinal cannabis as a substitute for pain and sleep...
By the time Amanda Stern was in her mid-40s, she no longer suffered from clinical depression . Her panic attacks, which had started in childhood, were mostly...